Cannabis consumption is associated with lower COVID-19 severity among hospitalized patients: a retrospective cohort analysis

Table 1 Baseline patient characteristics comparing subjects who did and did not actively consume cannabis products

Demographics	Active cannabis users	Non-users or previous cannabis users	P value
Demographics	(n = 69)	(n = 1762)	P value
^aAge (years), mean ± SD	44 ± 19	62 ± 19	< .001
^bMale sex, %	62	55	0.219
^aBMI (kg/m²), mean ± SD	28.2 ± 7.9	28.8 ± 7.4	0.554
^bRace, column %
White	48%	31%	0.005
Black	15%	9%	0.136
Asian	4%	8%	0.362
Latinx	28%	42%	0.017
Unknown/mixed race	6%	10%	0.401
^bTobacco use, column %
Never	55%	66%	0.053
Former use	24.6%	25.4%	1.000
Current use	20%	4%	< .001
Unknown use	0^c%	4%	0.110
^bComorbid conditions, column %
Diabetes mellitus	23%	37%	0.021
Cardiac disease	16%	24%	0.148
Chronic kidney disease	17%	27%	0.094
Chronic pulmonary disease	26%	26%	1.000
Chronic liver disease	3%	5%	0.581

Active cannabis use defined as cannabis consumption within 1 month of hospitalization. Any cannabis use thereafter are previous users. Non-users are patients with no history of cannabis use
BMI body mass index
^aWelch’s t test
^bFisher’s exact test
^c % of each level of variable within that particular group, not between groups

ISSN: 2522-5782